BridgeMD
Compares treatment options for Nausea With Vomiting Chemotherapy-Induced
Official title Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
ClinicalTrials.gov ID: NCT06080880
What this study is testing
What is Ondansetron every 3 weeks?
Ondansetron every 3 weeks is an investigational medicine, given as an once-weekly, being studied as a potential treatment for nausea with vomiting chemotherapy-induced.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years, no gender limit;
- Pathologically or cytologically confirmed malignant solid tumors;
- Scheduled to receive cisplatin-based chemotherapy combined with PD-1 blockade；
- TPS \> 1 %(PD-1);
- Adequate hematological function (leucocyte count ≥ 4000/μL [to convert to ×109/L,multiply by 0.001], hemoglobin ≥ 9.00 g/dL [to convert to grams per...
You likely can't join if
- Nausea or vomiting caused by reasons except for chemotherapy and PD-1 blockade;
- Participants with other malignant tumors history previously;
- Inability to read, comprehend, and finish questionnaires;
- Allergic to the drugs included in this study.
- Administered drugs with antiemetic activity within the 24 hours before receiving the first dose of study medication.
See the full eligibility criteria
- Age ≥ 18 years, no gender limit;
- Pathologically or cytologically confirmed malignant solid tumors;
- Scheduled to receive cisplatin-based chemotherapy combined with PD-1 blockade；
- TPS \> 1 %(PD-1);
- Adequate hematological function (leucocyte count ≥ 4000/μL [to convert to ×109/L,multiply by 0.001], hemoglobin ≥ 9.00 g/dL [to convert to grams per liter, multiply by 10], and platelet count ≥ 100 × 103/μL [to convert...
- Hepatic function (alanine aminotransferase and aspartate aminotransferase ≤ 2.0 times the upper limit of the reference ranges), and renal function (creatinine clearance ≥ 60 mL/min/1.73 m2 [to convert to millimeters per...
- Estimated survival time \> 6 months；
- ECOG 0-1 points；
- Participants being informed and signed written consents.
- Nausea or vomiting caused by reasons except for chemotherapy and PD-1 blockade;
- Participants with other malignant tumors history previously;
- Inability to read, comprehend, and finish questionnaires;
- Allergic to the drugs included in this study.
- Administered drugs with antiemetic activity within the 24 hours before receiving the first dose of study medication.
The study team makes the final eligibility decision.
Where it's taking place
- Wuhan, Hubei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wuhan, Hubei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.